Piper Sandler Increases Enfusion (NYSE:ENFN) Price Target to $11.50

Enfusion (NYSE:ENFN) had its price target increased by stock analysts at Piper Sandler from $10.00 to $11.50 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 8.18% from the company’s current price.

Separately, Stifel Nicolaus upped their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.25.

Enfusion Stock Up 1.5 %

Shares of NYSE ENFN opened at $10.63 on Monday. The company has a market cap of $1.37 billion, a price-to-earnings ratio of 265.82, a PEG ratio of 3.98 and a beta of 0.97. The firm’s fifty day moving average is $9.70 and its 200 day moving average is $9.00. Enfusion has a 52 week low of $7.52 and a 52 week high of $11.38.

Insiders Place Their Bets

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arizona State Retirement System bought a new stake in shares of Enfusion during the 2nd quarter valued at $86,000. Harbor Capital Advisors Inc. boosted its stake in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after acquiring an additional 1,315 shares in the last quarter. Belvedere Trading LLC purchased a new stake in Enfusion in the third quarter worth about $114,000. Paloma Partners Management Co bought a new position in shares of Enfusion during the third quarter valued at approximately $157,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Enfusion by 27.7% during the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after purchasing an additional 4,239 shares during the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.